Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-791826 · 1 trial · 1 indication
safety and tolerability
safety and tolerability
| Arm | Type | Description |
|---|---|---|
| Module A | EXPERIMENTAL | Single Ascending Dose |
| Module B | EXPERIMENTAL | Multiple Ascending Dose |
| Name | Type | Description |
|---|---|---|
| Prednisolone | DRUG | Specified dose on specified days |
| BMS-791826 | DRUG | Specified dose on specified days |
| Placebo | DRUG | Specified dose on specified days |
Inclusion Criteria: * Healthy male subjects as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiograms (ECGs), and clinical laboratory determinations * Body Mass Index (BMI) of 18 to 30 kilogram / square meter (kg/m2), inclusive * S...
BMS-791826 is an investigational small molecule being developed by Bristol-Myers Squibb for use in immunoscience, a therapeutic area focused on immunology. It is currently in Phase 1 clinical development. The drug has been studied in a clinical trial involving healthy male participants.
The specific molecular target of BMS-791826 has not been disclosed. It is being developed as a small molecule for immunoscience indications, which typically involve modulating immune system pathways, but the exact target is not publicly available.
BMS-791826 is being developed by Bristol-Myers Squibb Company, a global biopharmaceutical company. The company's stock is traded under the ticker symbol BMY on the New York Stock Exchange.
BMS-791826 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for its pharmacokinetics and pharmacodynamics in healthy volunteers.
BMS-791826 has been studied in one completed Phase 1 clinical trial with the identifier NCT03198013. This trial, titled 'A Study of Pharmacokinetics (PK) and Pharmacodynamics (PD) in Relation to Prednisolone in Healthy Males,' enrolled 120 healthy male participants in Australia.
No, BMS-791826 is not the same as prednisolone. Prednisolone is a corticosteroid used as a reference drug in the clinical trial to study the pharmacokinetics and pharmacodynamics of BMS-791826. BMS-791826 is a separate investigational small molecule being developed by Bristol-Myers Squibb.